May 29, 2019
Studies support dinutuximab beta in treating neuroblastoma – EUSA Pharma
EUSA Pharma’s studies of Qarziba in treatment of high-risk neuroblastoma support the use of dinutuximab beta as standard-of-care immunotherapy for high-risk neuroblastoma patients.